Roscovitine inhibits CaV3.1 (T-type) channels by preferentially affecting closed-state inactivation
Viktor Yarotskyy1, Keith S Elmslie
1Department of Pharmacology and Physiology, University of Rochester Medical Center, 601 Elmwood Avenue, Rochester, NY 14642, USA. viktor_yarotskyy@urmc.rochester.edu
Abstract:
T-type calcium channels (Ca(V)3) play an important role in many physiological and pathological processes, including cancerogenesis. Ca(V)3 channel blockers have been proposed as potential cancer treatments. Roscovitine, a trisubstituted purine, is a cyclin-dependent kinase (CDK) inhibitor that is currently undergoing phase II clinical trials as an anticancer drug and has been shown to affect calcium and potassium channel activity. Here, we investigate the effect of roscovitine on Ca(V)3.1 channels. Ca(V)3.1 channels were transiently expressed in human embryonic kidney 293 cells, and currents were recorded by using the whole-cell patch-clamp technique. Roscovitine blocks Ca(V)3.1 channels with higher affinity for depolarized cells (EC₅₀ of 10 μM), which is associated with a negative shift in the voltage dependence of closed-state inactivation. Enhanced inactivation is mediated by roscovitine-induced acceleration of closed-state inactivation and slowed recovery from inactivation. Small effects of roscovitine were also observed on T-channel deactivation and open-state inactivation, but neither could explain the inhibitory effect. Roscovitine inhibits Ca(V)3.1 channels within the therapeutic range (10-50 μM) in part by stabilizing the closed-inactivated state. The ability of roscovitine to block multiple mediators of proliferation, including CDKs and Ca(V)3.1 channels, may facilitate its anticancer properties.
Insights
Roscovitine, an anticancer drug, inhibits T-type calcium channels (Ca(V)3.1) by stabilizing their closed-inactivated state. This dual action on cyclin-dependent kinases and Ca(V)3.1 channels may enhance its anticancer efficacy.
Area of Science:
- Pharmacology
- Molecular Biology
- Oncology
Background:
- T-type calcium channels (Ca(V)3) are implicated in cancer development.
- Ca(V)3 channel blockers are explored as potential anti-cancer therapeutics.
- Roscovitine, a cyclin-dependent kinase (CDK) inhibitor, affects ion channel activity.
Purpose of the Study:
- To investigate the effect of roscovitine on Ca(V)3.1 channels.
- To determine the mechanism by which roscovitine inhibits Ca(V)3.1 channel activity.
- To assess the potential of roscovitine's dual inhibitory action in cancer treatment.
Main Methods:
- Transient expression of Ca(V)3.1 channels in human embryonic kidney 293 cells.
- Whole-cell patch-clamp technique to record ionic currents.
- Analysis of voltage dependence, inactivation, and deactivation kinetics.
Main Results:
- Roscovitine blocks Ca(V)3.1 channels with an EC₅₀ of 10 μM, showing higher affinity in depolarized cells.
- Roscovitine shifts the voltage dependence of closed-state inactivation negatively.
- Inhibition is primarily due to accelerated closed-state inactivation and slowed recovery from inactivation, with minor effects on deactivation and open-state inactivation.
Conclusions:
- Roscovitine inhibits Ca(V)3.1 channels within its therapeutic range (10-50 μM).
- The mechanism involves stabilization of the closed-inactivated state of Ca(V)3.1 channels.
- Roscovitine's combined inhibition of CDKs and Ca(V)3.1 channels may contribute to its anti-cancer properties.
Related Concept Videos
Ligand-Gated Ion Channel Receptor: Gating Mechanism
Receptor Downregulation in MVBs
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR activation may...
Non-gated Ion Channels
Compared to the gated ion channels, the non-gated channels, also known as leakage or passive channels, have no gating mechanism.
Non-gated Ion Channels
Compared to the gated ion channels, the non-gated channels, also known as leakage or passive channels, have no gating mechanism.
Voltage-gated Ion Channels
Generally, all voltage-gated ion channels have a 'voltage-sensing domain' that spans the lipid bilayer. The charged residues in the sensor move in response to the membrane potential changes that open the channel allowing ions movement. There are several types of...
Voltage-gated Ion Channels
Generally, all voltage-gated ion channels have a 'voltage-sensing domain' that spans the lipid bilayer. The charged residues in the sensor move in response to the membrane potential changes that open the channel allowing ions movement. There are several types of...


